Overview

A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To decide maximum tolerated dose and recommended dose of treatment using gemcitabine plus S-1 combination therapy in patients with biliary tract cancer undergoing resection without major hepatectomy
Phase:
Phase 1
Details
Lead Sponsor:
Kansai Hepatobiliary Oncology Group
Treatments:
Gemcitabine